The GAVI alliance said on Monday it had signed two advance purchase agreements with Chinese drugmakers Sinopharm and Sinovac to provide up to 550 million COVID-19 vaccines to the COVAX program.
The new deals include up to 170 million doses of the Sinopharm shot and up to 380 million doses of the Sinovac vaccine, through to the middle of 2022, the statement said. Sinovac confirmed the agreement in a statement.
“The agreements, which come at a time when the Delta variant is posing a rising risk to health systems, will begin to make 110 million doses immediately available to participants of the COVAX Facility, with options for additional doses,” GAVI said in a statement.
COVAX, which distributes vaccines to poorer countries, has struggled to meet its early commitments amid Indian export disruptions, forcing many countries to freeze their inoculation programs in their early phases.
However, its latest supply forecast shows that the program is on track to deliver more than 2 billion doses by early 2022.
Japan to ship millions more COVID-19 vaccines to Taiwan, Asian neighbors this weekJapan said on Tuesday it would ship millions more doses of AstraZeneca Plc’s COVID-19 vaccine to Asian neighbors this week as a continuation of ... Coronavirus
South Korea to give two different COVID-19 vaccine doses to 760,000 peopleSome 760,000 South Koreans who have received a first dose of AstraZeneca Plc’s COVID-19 vaccine will be offered Pfizer Inc’s vaccine as a second shot ... Coronavirus
GAVI in talks with China’s Sinovax to expand COVAX vaccine supplyThe GAVI vaccine alliance is in talks with Chinese drugmaker Sinovac Biotch to expand the COVAX dose-sharing portfolio available to poor countries ... Coronavirus